Clusterin glycosylation as diagnostic and prognostic biomarker for alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R43AG079709
- Recipient
-
Isoformix Inc. UEI NFTCN18E9BM5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $384,767
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Description
- Abstract
- Clusterin is the third most predominant genetic risk factor for late onset alzheimer's disease (ad). Clusterin facilitates the transport of soluble amyloid-b (AB) across the blood-brain barrier. Clusterin binds soluble forms of AB, preventing their aggregation into amyloid fibrils. However, there is no clear correlation between plasma or CSF clusterin concentration levels and ad, even though there is substantial evidence for upregulation of clusterin in the ad brain and colocalization with AB plaques. Clusterin is heavily glycosylated, with ~25% of its mass comprised of n-linked glycans. Glycosylation of clusterin is spatially and temporally regulated, and IT is important for its function as an extracellular chaperone. Glycosylation of clusterin may play an important role in the interaction with AB and its clearance. In this phase i project we propose to develop, optimize and validate a fast and cost-efficient mass spectrometry (MS)-immunoassay for detection of clusterin glycoforms that reveals both intact glycosylated clusterin and its component glycan structures. We will first optimize assay parameters such as antibody amount, sample volumes and dilutions, post-capture rinses, enzymatic release of sialic acids and the full glycans with sialidase and pngasef enzymes, and MS acquisition parameters. The assay performance will be validated by testing its robustness, accuracy, specificity, and reproducibility. We will use the assay on a cohort of matched CSF and plasma samples (n=106) from mildly impaired and healthy individuals at risk of ad. Data in the form of intact clusterin mass peaks shifts between plasma and CSF, mass shifts within samples following sialidase and pngasef treatment, the relative ratios of clusterin glycoforms, and IDS and ratios of the released glycans, will be compared across the cohort, and correlations with apoe genotype, apoe isoform-specific glycosylation, ASS42, TAU and ptau will be examined. The findings from the first cohort will be validated with a second cohort (n=100). Our value proposition is a fast and cost-effective assay for analyzing clusterin glycoforms and glycans that could be utilized for evaluating the role of clusterin glycosylation in ad pathogenesis. Clusterin glycosylation could serve as a biomarker for assessing ad risk, or as a target for the development of therapeutics that modify its glycosylation.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $384,767 |
Quick answers
Who received award R43AG079709?
R43AG079709 was awarded to Isoformix Inc. by National Institute on Aging (National Institutes of Health) on June 15, 2023.
How much is award R43AG079709 worth?
$384,767 has been obligated on R43AG079709.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award